UK rise in the use of oral and intravitreal antivirals in ARN treatment

Article

An investigation in the journal Eye has disclosed an increase in the use of oral and intravitreal antivirals for the treatment of acute retinal necrosis (ARN) in the UK.

An investigation in the journal Eye has disclosed an increase in the use of oral and intravitreal antivirals for the treatment of acute retinal necrosis (ARN) in the UK.

Dr T.F. Cochrane et al., Ophthalmology Department, Royal Victoria Hospital, Belfast Health and Social Care Trust, Northern Ireland, UK, conducted a prospective study on 52 eyes of 45 patients. UK ophthalmologists reported ARN cases by using the British Ophthalmological Surveillance Unit (BOSU) report card system.

Of the patients studied, there were 20 females and 25 males aged between 10 and 94 years. It was found that 8 patients had a history of herpetic CNS disease. A total of 13 patients underwent aqueous sampling, 27 underwent vitreous sampling and 4 underwent cerebrospinal fluid (CSF) sampling.

For 76% of cases ophthalmologists administered intravenous antivirals and 24% received oral antivirals only. The visual outcome at six months was under 6/60 in 48% of affected eyes.

The study results strongly suggest that patients with a history of herpetic CNS disease should immediately report any visual symptoms.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.